相关实验视频

Updated: Jun 10, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

影响日本牛皮患者治疗持续性的因素处方生物药:使用保险索赔数据库的现实研究

Celine Miyazaki¹, Junya Masuda², Phiona I-Ching Tsai³

¹Value, Evidence and Access Department, Janssen Pharmaceutical K.K., Nishi Kanda 3-5-2, Chiyoda-ku, Tokyo, 101-0065, Japan. CMiyazak@its.jnj.com.

Dermatology and therapy

|October 15, 2024

概括

因弗利西马布治疗时间中位数最长,而古塞尔库马布治疗时间中位数最长,而古塞尔库马布治疗时间中位数最长的1年生存期是牛皮 (PsO) 生物药物. 患者的性别和特定的PsO诊断代码影响了日本的治疗持续性.

科学领域:

皮肤病学皮肤病学
药理学药理学是指药理学的学科.
医疗保健服务研究医疗服务研究

背景情况:

生物治疗的持续性对于管理诸如牛皮 (PsO) 等慢性疾病至关重要,这会影响健康结果和成本.
在日本进行的有限研究已经探索了影响PsO患者生物持久性的因素.
这项研究评估了日本PsO患者的现实世界生物治疗持久性和相关因素.

研究的目的:

评估皮病患者的生物治疗持续性,包括皮病患者的中位持续时间和整体存活率.
在日本的现实环境中识别与生物治疗持久性相关的因素.
为了比较不同生物制剂的持久性,以及生物原始和生物经验丰富的患者之间的持久性.

主要方法:

来自日本医学数据中心 (JMDC) 数据库 (2016-2020) 的保险索赔数据的回顾性分析.
包括接受生物治疗的18岁以上牛皮患者 (ICD代码:L40.x).
使用卡普兰-梅尔生存率和考克斯比例危险回归来分析治疗持久性的因素,如性别,年龄和并发症.

主要成果:

因弗利西马布治疗时间最长 (33.6个月),而布罗达卢马布治疗时间最短 (9.7个月).
古塞尔库马布显示了最高的1年治疗存活率 (83%),而不是布罗达卢马布 (45%).
男性性别和特定的牛皮诊断代码 (L40.0,L40.1,L40.9) 与治疗持续时间的增加有关.

结论:

在日本牛皮患者的评估生物药物中,infliximab和guselkumab表现出良好的持久性概况.
患者的性别和特定的牛皮诊断代码是生物治疗持久性的重要预测因素.
研究结果为优化临床实践中牛皮的长期生物治疗策略提供了见解.

关键词:

生物制剂生物制剂生物制剂这就是Guselkumab.这是JMDC的目标.日本日本日本日本日本.牛皮是一种病.治疗持续性治疗持续性治疗生存率治疗生存率

更多相关视频

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients

Published on: March 1, 2024

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

相关概念视频

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...

Factors Influencing Drug Absorption: Disease States and Pharmacology

Factors Influencing Drug Absorption: Disease States and Pharmacology

Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...

Factors Affecting Drug Response: Overview

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...